ICU

National Study: Ballad Health, ETSU Trauma Consolidation Saves Hundreds of Lives

Retrieved on: 
Monday, April 1, 2024

In terms of lives, the reduction in the rate of deaths equates to hundreds of lives saved due to the successful consolidation of the region’s two Level 1 trauma centers.

Key Points: 
  • In terms of lives, the reduction in the rate of deaths equates to hundreds of lives saved due to the successful consolidation of the region’s two Level 1 trauma centers.
  • It found the patients with the highest likelihood of death due to severity had significantly improved survival rates post-consolidation.
  • Assisted by national experts, the advisory group recommended consolidation of the region’s two Level 1 trauma centers into one at Johnson City Medical Center, while maintaining Level 3 trauma services at Holston Valley Medical Center and Bristol Regional Medical Center.
  • “Excellent trauma care is a team effort from every corner of our region,” said Ballad Health Chairman and CEO Alan Levine.

Spectral Medical Announces Fourth Quarter and Fiscal 2023 Results and Provides Corporate Update

Retrieved on: 
Thursday, March 28, 2024

TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2023 and provided a corporate update.
  • Dr. John Kellum, Chief Medical Officer of Spectral Medical, stated, “We have witnessed robust enrollment activity to start 2024.
  • addition of two new trial sites in the fourth quarter – the Mayo Clinic and Emory Healthcare.
  • The Company concluded the 2023 year with cash of $2,952,000 compared to $8,414,000 cash on hand as of December 31, 2022.

New Study Finds AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration and Significantly Reduce False Alarms for Clinicians

Retrieved on: 
Tuesday, April 9, 2024

The prediction models used in the study are a part of CLEW’s intelligent clinical surveillance platform.

Key Points: 
  • The prediction models used in the study are a part of CLEW’s intelligent clinical surveillance platform.
  • It also supports the health system with capacity management, by providing early identification of potential bottlenecks caused by unexpected deterioration.
  • In addition to demonstrating its superior accuracy, the study concluded that the CLEW system generated 50-times fewer alarms than other leading systems.
  • In busy and overburdened critical care environments, this can greatly reduce alarm fatigue and the associated cognitive burden on caregivers.

Collette Health Debuts Three Major Platform Enhancements at AONL 2024 Conference to Increase Patient Safety

Retrieved on: 
Tuesday, April 9, 2024

Collette Health , a leading provider of continuous virtual patient observation solutions, announced today at the 2024 American Organization for Nursing Leadership (AONL) Conference three new major platform enhancements to increase patient safety and allow care from anywhere.

Key Points: 
  • Collette Health , a leading provider of continuous virtual patient observation solutions, announced today at the 2024 American Organization for Nursing Leadership (AONL) Conference three new major platform enhancements to increase patient safety and allow care from anywhere.
  • “This is a major milestone for Collette Health, and we’re proud to unveil and introduce these new features at AONL in front of thousands of nursing leaders,” said Christine Gall, Chief Nursing Officer at Collette Health.
  • Collette Health uses a strategic and human-enabled application of AI and machine learning (ML) with its new “follow patient” feature.
  • Collette Health will be exhibiting and demonstrating its platform at the AONL Conference in New Orleans, April 9-10.

Family caregivers can help shape the outcomes for their loved ones – an ICU nurse explains their vital role

Retrieved on: 
Tuesday, April 9, 2024

Marie landed in the intensive care unit where I am a bedside nurse because she was too agitated and needed more oxygen.

Key Points: 
  • Marie landed in the intensive care unit where I am a bedside nurse because she was too agitated and needed more oxygen.
  • As a seasoned bedside critical care nurse, I see firsthand the benefits that family caregivers bring to patient care in the hospital.
  • I also witness the emotional stress that caregivers experience when their loved one comes to the ICU.

Caregivers often battle anxiety and depression

  • From making medical decisions to advocating for their loved one, family caregivers have many important roles when their loved one is in the hospital.
  • However, caregivers carry heavy emotional burdens while supporting loved ones at the hospital.
  • Up to 70% of first-degree relatives of ICU survivors suffer from anxiety symptoms, more than a third suffer from depression, and many can experience symptoms of post-traumatic stress disorder, or PTSD.

Communication is critical

  • As you provide information about the patient at home, the medical team should be giving you updates about the patient’s condition in the hospital.
  • Knowing what to ask is essential to effective communication at the hospital.
  • Once familiar with your new environment, you may feel more at ease to truly be present for your loved one.
  • Every day, the interdisciplinary medical team sees each patient to discuss updates and treatment plans, and answers questions for the patient and their family.
  • Research has also shown that rounds relieve anxiety and stress among family caregivers due to the consistent daily communication and emotional support that they provide.

Nurses can be helpful

  • After clinical rounds, the interdisciplinary team of doctors and nurses establishes a daily plan of care for your loved one, which will be carried out by your bedside nurse.
  • The nurse will give the ordered medications, perform necessary clinical tasks and assess the patient for their response to the treatment.
  • Nurses are the most accessible resource you have when your loved one is in the hospital.

The importance of routines and familiarity

  • Preventing ICU delirium through reorientation and familiar faces can help prevent this serious complication and can even reduce their hospital stay.
  • Most families that come to the hospital describe the support they received from the medical team in a positive way.


Courtney Graetzer does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

To Bolster Global Efforts in Combating Antibiotic-Resistant Bacteria KFSH&RC Scientists Discover New Bacteria Species: Riyadhensis

Retrieved on: 
Monday, March 25, 2024

RIYADH, Saudi Arabia, March 25, 2024 (GLOBE NEWSWIRE) -- In a ground-breaking development, scientists at King Faisal Specialist Hospital and Research Centre (KFSH&RC) have identified a new species of bacteria, referred to as "Stenotrophomonas Riyadhensis" through the application of whole-genome sequencing (WGS) technology. This discovery signifies a major advancement in understanding how bacteria interact with existing drugs, paving the way for innovative therapeutic strategies. Such efforts are essential in the global fight against antibiotic-resistant bacteria, highlighting KFSH&RC’s advanced research capabilities and its leading role in fostering scientific discoveries and enhancing patient care.

Key Points: 
  • This discovery signifies a major advancement in understanding how bacteria interact with existing drugs, paving the way for innovative therapeutic strategies.
  • Such efforts are essential in the global fight against antibiotic-resistant bacteria, highlighting KFSH&RC’s advanced research capabilities and its leading role in fostering scientific discoveries and enhancing patient care.
  • This represents substantial progress in combating antibiotic resistance, developing pharmaceuticals, and preventing the spread of diseases.
  • Furthermore, this approach lays the groundwork for scientific collaboration at all levels, enhancing global efforts to combat antibiotic resistance.

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Retrieved on: 
Monday, March 18, 2024

We have never been more focused on our mission and goals. Every team member at Daxor sees both the remarkable strides the company has made over the past year solidifying its position as the global leader in blood volume measurement technology and the promise of what our rapid expansion means for both the company and the tens of millions of patients whose care we are eager to significantly improve. In every area 2023 and the strong start of 2024 has shown substantial progress for the company -- in revenue growth, new customer acquisitions, increasing utilization of our products by existing customers, next generation systems completed and under Food and Drug Administration (FDA) review, positive clinical studies, new patents granted and pending, successful National Institutes of Health (NIH) grant awards, Department of Defense (DoD) contracts awarded, and further research and development for groundbreaking products set to launch in subsequent fiscal years. I will detail below more in these areas but first wish to review why our company’s mission to commercialize the products that enable optimal patient care is so vital.

Key Points: 
  • Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 15, 2023 from CEO & President, Michael Feldschuh.
  • Many of these markers are costly, some are invasive, and none are accurate – in contrast to Daxor’s proven 98% accurate system.
  • Care teams cannot effectively treat what they do not correctly diagnose, so our rapid accurate diagnostic test is a game-changer.
  • Daxor has been reporting as an investment company under the Investment Company Act of 1940 since January 1, 2012.

ICU Medical to Present at the KeyBanc Life Sciences & MedTech Investor Forum

Retrieved on: 
Wednesday, March 13, 2024

SAN CLEMENTE, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the KeyBanc Life Sciences & MedTech Investor Forum being held virtually March 19-20, 2024.

Key Points: 
  • SAN CLEMENTE, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the KeyBanc Life Sciences & MedTech Investor Forum being held virtually March 19-20, 2024.
  • ICU Medical’s presentation will be on Wednesday, March 20, 2024 at 11:15 a.m. PT (2:15 p.m.
  • Company management will also be participating in one-on-one meetings on Wednesday, March 20, 2024.
  • The presentation will be webcast live and can be accessed by going to the Company’s website at http://www.icumed.com , clicking on the Investors tab and clicking on the Event Calendar tab.

Asahi Kasei Medical and AW Technologies enter exclusive distribution agreement for TrachFlush in Japan

Retrieved on: 
Wednesday, April 3, 2024

AW Technologies and Asahi Kasei Medical, a core operating company of the Asahi Kasei Group, have entered into an exclusive distribution agreement in Japan for AW Technologies’ TrachFlush™ device.

Key Points: 
  • AW Technologies and Asahi Kasei Medical, a core operating company of the Asahi Kasei Group, have entered into an exclusive distribution agreement in Japan for AW Technologies’ TrachFlush™ device.
  • AW Technologies is currently in the process of medical device registration of the TrachFlush in Japan, with market launch targeted in fiscal 2024.
  • Adam Hansen, CEO of AW Technologies, commented, "We are very pleased and excited to announce our partnership with Asahi Kasei Medical.
  • This partnership is very important for AW Technologies, and Asahi Kasei Medical will play a very important role in our expansion of TrachFlush globally.

Global Ventilators Market Focused Insights and Outlook 2024-2029 - KoninKlijke Philips, Hamilton Medical, Resmed, Medtronic & GE Healthcare Lead the Market - ResearchAndMarkets.com

Retrieved on: 
Monday, March 18, 2024

The global ventilators market, valued at USD 1.75 billion in 2023, is expected to grow at a CAGR of 6.50% from 2023 to 2029.

Key Points: 
  • The global ventilators market, valued at USD 1.75 billion in 2023, is expected to grow at a CAGR of 6.50% from 2023 to 2029.
  • The global ventilators market is one of the fastest-growing segments in the medical devices market.
  • The changing healthcare services in emerging markets and significant achieved development with developed countries consistently drive the ventilator market growth.
  • KoninKlijke Philips, Hamilton Medical, Resmed, Medtronic plc, & GE Healthcare are some leading players currently dominating the global ventilators market.